The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research.
The Journal of Clinical Oncology (JCO) serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.
JCO's Impact Factor is 32.956 as reported by Clarivate in its 2020 Journal Citation Reports. The publication is indexed in the following services: Abstracts of Health Care Management Studies, Automatic Subject Citation Index, Chemical Abstracts, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Current Contents (Clinical Medicine, ISI/BioMed, Life Sciences, Science Citation Index, SCISEARCH), EMBASE/Excerpta Medica, Index Medicus/MEDLINE, Neuroscience Citation Index, and EBSCOHOST Electronic Journals Service.
JCO is published by Wolters Kluwer. Harborside serves as the advertising sales representative for this publication.
Jonathan W. Friedberg, MD, MMSc
Dr. Friedberg began his tenure as Editor-in-Chief of the Journal of Clinical Oncology (JCO) in June 2021 after serving as Associate Editor since 2011. As ASCO's flagship journal, JCO publishes cutting-edge research on the diagnosis and treatment of patients with cancer and is one of the most highly cited oncology journals in the world.
A hematologic oncologist for more than 20 years, Dr. Friedberg is currently Director of the Wilmot Cancer Institute and Samuel Durand Professor of Medicine at the University of Rochester Medical Center in Rochester, New York. He chairs the SWOG Lymphoma Committee and is a U.S. National Institutes of Health R01-funded lymphoma researcher.View Editorial Board
The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. JCO has approximately 17,000 U.S.-based and 3,700 international subscribers, including ASCO members and other physicians and researchers worldwide, as well as more than 7,500 institutional subscribers.
Advertising opportunities exist in print, the website, for electronic table of contents and targeted emails, and more. Further details are available in the media kit and rate card. Please contact our advertising representatives with any inquiries. All advertisements are subject to ASCO's Advertising Policy.